A placebo-controlled trial of atomoxetine in marijuana-dependent individuals with attention deficit hyperactivity disorder

Aimee L. McRae-Clark, Rickey E. Carter, Therese K. Killeen, Matthew J. Carpenter, Kathleen G. White, Kathleen T. Brady

Research output: Contribution to journalArticle

45 Citations (Scopus)

Abstract

This study evaluated the effects of atomoxetine on the symptoms of attention deficit hyperactivity disorder (ADHD) and marijuana use in marijuana-dependent adults. In conjunction with motivational interviewing, participants received either atomoxetine (n = 19) or matching placebo (n = 19) for 12 weeks. Participants randomized to atomoxetine had greater improvement in ADHD on the Clinical Global Impression-Improvement scale than participants treated with placebo. No treatment group differences in self-rated ADHD symptoms, overall Wender-Reimherr Adult Attention Deficit Disorder Scale scores, or marijuana use outcomes were noted. These results suggest that atomoxetine may improve some ADHD symptoms but does not reduce marijuana use in this population.

Original languageEnglish (US)
Pages (from-to)481-489
Number of pages9
JournalAmerican Journal on Addictions
Volume19
Issue number6
DOIs
StatePublished - Nov 2010

Fingerprint

Cannabis
Attention Deficit Disorder with Hyperactivity
Placebos
Motivational Interviewing
Atomoxetine Hydrochloride
Population
Therapeutics

ASJC Scopus subject areas

  • Medicine (miscellaneous)
  • Psychiatry and Mental health
  • Clinical Psychology

Cite this

A placebo-controlled trial of atomoxetine in marijuana-dependent individuals with attention deficit hyperactivity disorder. / McRae-Clark, Aimee L.; Carter, Rickey E.; Killeen, Therese K.; Carpenter, Matthew J.; White, Kathleen G.; Brady, Kathleen T.

In: American Journal on Addictions, Vol. 19, No. 6, 11.2010, p. 481-489.

Research output: Contribution to journalArticle

McRae-Clark, Aimee L. ; Carter, Rickey E. ; Killeen, Therese K. ; Carpenter, Matthew J. ; White, Kathleen G. ; Brady, Kathleen T. / A placebo-controlled trial of atomoxetine in marijuana-dependent individuals with attention deficit hyperactivity disorder. In: American Journal on Addictions. 2010 ; Vol. 19, No. 6. pp. 481-489.
@article{a4e933435ff94b7b8649523b2e87c074,
title = "A placebo-controlled trial of atomoxetine in marijuana-dependent individuals with attention deficit hyperactivity disorder",
abstract = "This study evaluated the effects of atomoxetine on the symptoms of attention deficit hyperactivity disorder (ADHD) and marijuana use in marijuana-dependent adults. In conjunction with motivational interviewing, participants received either atomoxetine (n = 19) or matching placebo (n = 19) for 12 weeks. Participants randomized to atomoxetine had greater improvement in ADHD on the Clinical Global Impression-Improvement scale than participants treated with placebo. No treatment group differences in self-rated ADHD symptoms, overall Wender-Reimherr Adult Attention Deficit Disorder Scale scores, or marijuana use outcomes were noted. These results suggest that atomoxetine may improve some ADHD symptoms but does not reduce marijuana use in this population.",
author = "McRae-Clark, {Aimee L.} and Carter, {Rickey E.} and Killeen, {Therese K.} and Carpenter, {Matthew J.} and White, {Kathleen G.} and Brady, {Kathleen T.}",
year = "2010",
month = "11",
doi = "10.1111/j.1521-0391.2010.00076.x",
language = "English (US)",
volume = "19",
pages = "481--489",
journal = "American Journal on Addictions",
issn = "1055-0496",
publisher = "Wiley-Blackwell",
number = "6",

}

TY - JOUR

T1 - A placebo-controlled trial of atomoxetine in marijuana-dependent individuals with attention deficit hyperactivity disorder

AU - McRae-Clark, Aimee L.

AU - Carter, Rickey E.

AU - Killeen, Therese K.

AU - Carpenter, Matthew J.

AU - White, Kathleen G.

AU - Brady, Kathleen T.

PY - 2010/11

Y1 - 2010/11

N2 - This study evaluated the effects of atomoxetine on the symptoms of attention deficit hyperactivity disorder (ADHD) and marijuana use in marijuana-dependent adults. In conjunction with motivational interviewing, participants received either atomoxetine (n = 19) or matching placebo (n = 19) for 12 weeks. Participants randomized to atomoxetine had greater improvement in ADHD on the Clinical Global Impression-Improvement scale than participants treated with placebo. No treatment group differences in self-rated ADHD symptoms, overall Wender-Reimherr Adult Attention Deficit Disorder Scale scores, or marijuana use outcomes were noted. These results suggest that atomoxetine may improve some ADHD symptoms but does not reduce marijuana use in this population.

AB - This study evaluated the effects of atomoxetine on the symptoms of attention deficit hyperactivity disorder (ADHD) and marijuana use in marijuana-dependent adults. In conjunction with motivational interviewing, participants received either atomoxetine (n = 19) or matching placebo (n = 19) for 12 weeks. Participants randomized to atomoxetine had greater improvement in ADHD on the Clinical Global Impression-Improvement scale than participants treated with placebo. No treatment group differences in self-rated ADHD symptoms, overall Wender-Reimherr Adult Attention Deficit Disorder Scale scores, or marijuana use outcomes were noted. These results suggest that atomoxetine may improve some ADHD symptoms but does not reduce marijuana use in this population.

UR - http://www.scopus.com/inward/record.url?scp=78349292268&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78349292268&partnerID=8YFLogxK

U2 - 10.1111/j.1521-0391.2010.00076.x

DO - 10.1111/j.1521-0391.2010.00076.x

M3 - Article

VL - 19

SP - 481

EP - 489

JO - American Journal on Addictions

JF - American Journal on Addictions

SN - 1055-0496

IS - 6

ER -